Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation
CNS Spectrums December 10, 2020 Nelson B. Rodrigues, Ashley Siegel, Orly Lipsitz et al. 17 citations
Intravenous (IV) ketamine effectively reduces symptoms of depression, suicidal ideation, anxiety, and anhedonia in adults with treatment-resistant depression, regardless of whether they have previously undergone neurostimulation. In a retrospective analysis of 238 patients, those without prior neurostimulation experienced an average 6.4-point reduction on a depression severity scale, while those with a history of neurostimulation showed a 4.3-point reduction. No significant differences emerged between the groups, indicating that IV ketamine benefits even highly intractable patients.